CME Stock Analysis — CME Group
Sector: Financials
AI Verdict
You’re paying a premium the numbers don’t yet support—CME trades at 21.1x forward earnings for 8.0% growth, so unless its exchange moat delivers upside surprises, the risk of multiple compression is real.
Competitive Moat
CME Group operates the world’s largest derivatives exchange, with entrenched network effects as traders must transact where liquidity is deepest. Its clearinghouse function and regulatory status make it extremely difficult for new entrants to replicate its infrastructure or trust advantage.
Summary
CME’s forward P/E of 21.1x and 8.0% expected EPS growth put it at the high end of financial sector valuations, reflecting its unique exchange moat.
Where It Stands
CME is up -1.50% over the past year, trades at 21.1x next year’s earnings (vs. 14x sector median), and its RSI of 65.8 signals elevated pullback risk.
Key Metrics
- RSI: 65.8 — Near Overbought
- Trailing P/E: 22.8x
- Forward P/E: 21.1x
- PEG Ratio: 2.85
- Earnings Growth: +0.1%
- Revenue Growth: +0.2%
- Market Cap: $97.0B
- Dividend Yield: 0.02%
- 1-Year Return: -1.50%
- 52-Week High: $329.16
- 52-Week Low: $218.31
Analyst Consensus
12 Buy · 6 Hold · 3 Sell (21 analysts)
Bull Case
CME’s 21.1x forward P/E is justified if it delivers the 8.0% EPS growth analysts expect, given its irreplaceable market structure and $97.0B scale.
Bear Case
If the P/E compresses from 21.1x to the sector median of 14x, the stock could lose over 33% even if earnings meet expectations, especially with an RSI of 65.8 indicating short-term overbought conditions.
Catalyst to Watch
Watch for quarterly volume and open interest updates—sustained growth above the 16.6% revenue pace could support the premium multiple.